This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1756-1758, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureusdagger

Yuzhi Dong,1 Xilin Zhao,1 John Domagala,2 and Karl Drlica1,*

Public Health Research Institute, New York, New York 10016,1 and Parke-Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 481052

Received 7 December 1998/Returned for modification 25 January 1999/Accepted 12 April 1999

When Mycobacterium bovis BCG and Staphylococcus aureus were plated on agar containing increasing concentrations of fluoroquinolone, colony numbers exhibited a sharp drop, followed by a plateau and a second sharp drop. The plateau region correlated with the presence of first-step resistant mutants. Mutants were not recovered at concentrations above those required for the second sharp drop, thereby defining a mutant prevention concentration (MPC). A C-8-methoxy group lowered the MPC for an N-1-cyclopropyl fluoroquinolone.

* Corresponding author. Mailing address: Public Health Research Institute, 455 First Ave., New York, NY 10016. Phone: (212) 578-0830. Fax: (212) 578-0804. E-mail: drlica{at}phri.nyu.edu.

dagger Publication 65 from the Public Health Research Institute TB Center.

Antimicrobial Agents and Chemotherapy, July 1999, p. 1756-1758, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Allen, G. P., Hankins, C. D. (2009). Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. J Antimicrob Chemother 64: 359-363 [Abstract] [Full Text]  
  • Ciolino, J. B., Hoare, T. R., Iwata, N. G., Behlau, I., Dohlman, C. H., Langer, R., Kohane, D. S. (2009). A Drug-Eluting Contact Lens. IOVS 50: 3346-3352 [Abstract] [Full Text]  
  • Becnel Boyd, L., Maynard, M. J., Morgan-Linnell, S. K., Horton, L. B., Sucgang, R., Hamill, R. J., Jimenez, J. R., Versalovic, J., Steffen, D., Zechiedrich, L. (2009). Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates. Antimicrob. Agents Chemother. 53: 229-234 [Abstract] [Full Text]  
  • Cairns, B. J., Payne, R. J. H. (2008). Bacteriophage Therapy and the Mutant Selection Window. Antimicrob. Agents Chemother. 52: 4344-4350 [Abstract] [Full Text]  
  • German, N., Malik, M., Rosen, J. D., Drlica, K., Kerns, R. J. (2008). Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones. Antimicrob. Agents Chemother. 52: 3915-3921 [Abstract] [Full Text]  
  • Michel, J.-B., Yeh, P. J., Chait, R., Moellering, R. C. Jr., Kishony, R. (2008). Drug interactions modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. USA 105: 14918-14923 [Abstract] [Full Text]  
  • Zhao, X., Drlica, K. (2008). A unified anti-mutant dosing strategy. J Antimicrob Chemother 62: 434-436 [Abstract] [Full Text]  
  • Okumura, R., Hirata, T., Onodera, Y., Hoshino, K., Otani, T., Yamamoto, T. (2008). Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 62: 98-104 [Abstract] [Full Text]  
  • Nomura, K., Morikawa, N., Ikawa, K., Ikeda, K., Fujimoto, Y., Shimizu, D., Taniguchi, K., Shimura, K., Kanbayashi, Y., Komori, T., Matsumoto, Y., Fujita, N., Shimazaki, C., Taniwaki, M. (2008). Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 61: 892-900 [Abstract] [Full Text]  
  • Oonishi, Y., Mitsuyama, J., Yamaguchi, K. (2007). Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. J Antimicrob Chemother 60: 1030-1037 [Abstract] [Full Text]  
  • Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
  • Goessens, W. H. F., Mouton, J. W., ten Kate, M. T., Bijl, A. J., Ott, A., Bakker-Woudenberg, I. A. J. M. (2007). Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J Antimicrob Chemother 59: 507-516 [Abstract] [Full Text]  
  • Goldstein, F. (2007). The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 59: 1-4 [Abstract] [Full Text]  
  • Ba, B. B., Arpin, C., Vidaillac, C., Chausse, A., Saux, M.-C., Quentin, C. (2006). Activity of Gatifloxacin in an In Vitro Pharmacokinetic-Pharmacodynamic Model against Staphylococcus aureus Strains either Susceptible to Ciprofloxacin or Exhibiting Various Levels and Mechanisms of Ciprofloxacin Resistance.. Antimicrob. Agents Chemother. 50: 1931-1936 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Komp Lindgren, P., Hughes, D., Cars, O. (2006). Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57: 1116-1121 [Abstract] [Full Text]  
  • Drlica, K., Zhao, X., Blondeau, J. M., Hesje, C. (2006). Low Correlation between MIC and Mutant Prevention Concentration. Antimicrob. Agents Chemother. 50: 403-404 [Full Text]  
  • Strahilevitz, J., Truong-Bolduc, Q. C., Hooper, D. C. (2005). DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases. Antimicrob. Agents Chemother. 49: 5051-5057 [Abstract] [Full Text]  
  • Wetzstein, H.-G. (2005). Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance. Antimicrob. Agents Chemother. 49: 4166-4173 [Abstract] [Full Text]  
  • Marcusson, L. L., Olofsson, S. K., Lindgren, P. K., Cars, O., Hughes, D. (2005). Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55: 938-943 [Abstract] [Full Text]  
  • Strahilevitz, J., Hooper, D. C. (2005). Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrob. Agents Chemother. 49: 1949-1956 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Konstantinides, G. N., Rotschafer, J. C. (2005). Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens. Antimicrob. Agents Chemother. 49: 1633-1635 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
  • Li, X., Mariano, N., Rahal, J. J., Urban, C. M., Drlica, K. (2004). Quinolone-Resistant Haemophilus influenzae in a Long-Term-Care Facility: Nucleotide Sequence Characterization of Alterations in the Genes Encoding DNA Gyrase and DNA Topoisomerase IV. Antimicrob. Agents Chemother. 48: 3570-3572 [Abstract] [Full Text]  
  • Maeda, Y., Kiba, A., Ohnishi, K., Hikichi, Y. (2004). Implications of Amino Acid Substitutions in GyrA at Position 83 in Terms of Oxolinic Acid Resistance in Field Isolates of Burkholderia glumae, a Causal Agent of Bacterial Seedling Rot and Grain Rot of Rice. Appl. Environ. Microbiol. 70: 5613-5620 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Rodriguez, J. C., Cebrian, L., Lopez, M., Ruiz, M., Jimenez, I., Royo, G. (2004). Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 53: 441-444 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Linde, H.-J., Lehn, N. (2004). Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother 53: 252-257 [Abstract] [Full Text]  
  • Lu, T., Drlica, K. (2003). In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028 [Abstract] [Full Text]  
  • Paladino, J. A., Sunderlin, J. L., Forrest, A., Schentag, J. J. (2003). Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52: 457-463 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Li, X., Hansen, G., Blondeau, J., Drlica, K. (2003). Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 52: 61-64 [Abstract] [Full Text]  
  • Ince, D., Zhang, X., Hooper, D. C. (2003). Activity of and Resistance to Moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1410-1415 [Abstract] [Full Text]  
  • Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B., Drlica, K. (2003). Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1023-1027 [Abstract] [Full Text]  
  • Kishii, R., Takei, M., Fukuda, H., Hayashi, K., Hosaka, M. (2003). Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 77-81 [Abstract] [Full Text]  
  • Li, X., Zhao, X., Drlica, K. (2002). Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin. Antimicrob. Agents Chemother. 46: 522-524 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Li, X., Drlica-Wagner, A., Wang, J.-Y., Domagala, J., Drlica, K. (2001). Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2703-2709 [Abstract] [Full Text]  
  • Ince, D., Hooper, D. C. (2001). Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2755-2764 [Abstract] [Full Text]  
  • Nash, K. A. (2001). Effect of Drug Concentration on Emergence of Macrolide Resistance in Mycobacterium avium. Antimicrob. Agents Chemother. 45: 1607-1614 [Abstract] [Full Text]  
  • O'Neill, A. J., Chopra, I., Martínez, J. L., Baquero, F. (2001). Use of Mutator Strains for Characterization of Novel Antimicrobial Agents. Antimicrob. Agents Chemother. 45: 1599-1600 [Full Text]  
  • Klepser, M. E., Ernst, E. J., Petzold, C. R., Rhomberg, P., Doern, G. V. (2001). Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Streptococcus pneumoniae in a Dynamic In Vitro Model. Antimicrob. Agents Chemother. 45: 673-678 [Abstract] [Full Text]  
  • Blondeau, J. M., Zhao, X., Hansen, G., Drlica, K. (2001). Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 433-438 [Abstract] [Full Text]  
  • Sindelar, G., Zhao, X., Liew, A., Dong, Y., Lu, T., Zhou, J., Domagala, J., Drlica, K. (2000). Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria. Antimicrob. Agents Chemother. 44: 3337-3343 [Abstract] [Full Text]  
  • Ince, D., Hooper, D. C. (2000). Mechanisms and Frequency of Resistance to Premafloxacin in Staphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions. Antimicrob. Agents Chemother. 44: 3344-3350 [Abstract] [Full Text]  
  • Negri, M.-C., Lipsitch, M., Blázquez, J., Levin, B. R., Baquero, F. (2000). Concentration-Dependent Selection of Small Phenotypic Differences in TEM beta -Lactamase-Mediated Antibiotic Resistance. Antimicrob. Agents Chemother. 44: 2485-2491 [Abstract] [Full Text]  
  • Dong, Y., Zhao, X., Kreiswirth, B. N., Drlica, K. (2000). Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44: 2581-2584 [Abstract] [Full Text]  
  • Fournier, B., Zhao, X., Lu, T., Drlica, K., Hooper, D. C. (2000). Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis. Antimicrob. Agents Chemother. 44: 2160-2165 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Drlica, K. (1999). Gatifloxacin Activity against Quinolone-Resistant Gyrase: Allele-Specific Enhancement of Bacteriostatic and Bactericidal Activities by the C-8-Methoxy Group. Antimicrob. Agents Chemother. 43: 2969-2974 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»